When to give blood pressure lowering agents after stroke onset remains a topical question for which there is no definitive answer. This is nicely brought out by our two Leading opinions where Thanh Phan quite rightly points out that all the randomised clinical trial evidence (mainly from the PROGRESS trial) requires patients to be stable for two weeks prior to drug administration. This would usually mean that patients have been discharged from the hospital before medication commenced. Conversely, as presented by Tim Kleinig in his opinion piece it is generally accepted that uptake of and adherence to therapy is suboptimal when care plans including drug administration are not implemented prior to patient discharge. This was also found in the EXPRESS study where drug administration prior to discharge was found to be more reliably implemented.
This area of clinical practice uncertainty is just one of the myriad of examples where the art of medicine must still come into play until more definitive evidence for practice guideline are generated. Always fertile ground for future clinical trials! Clinical trials may be either small and focussed on a specific stroke subtype, or large and pragmatic, incorporating almost every form of stroke. There are arguments for each, and gradations between.
We have two protocols in this edition, which beautifully illustrate large pragmatic trials, designed to answer simple questions in large populations. The results of the Family-Led RehabiliTaTion aftEr Stroke in INDia (ATTEND) trail have already been presented at the recent World Stroke Congress in Hyderabad, and demonstrated a neutral benefit for home based rehabilitation versus standard care in an Indian population. The Head Position in acute ischemic Stroke Trial (HEADPOST), again tests a simple intervention, this time determining as to whether keeping a patient horizontal for a period post stroke, versus sitting will improve outcomes. By their very nature, large pragmatic trials influence clinical practice and these two will be no exception.
Home based care is also a focus of an economic analysis by Joo et al, who demonstrates an economic analysis of patients with stroke in China who demonstrated that approx. 20 hours per week were dedicated to this purpose, with significant financial implications. Of course the burden of disease from stroke in China is enormous given the 2.3 billion-population. Hence, it will be intriguing to see other aspects of stroke medicine presented in out forthcoming edition 'Focus on China'.
Watch this space!
